psilocybin
Phase 2- Indications
- Adjustment disorder, Palliative care
Company intelligence / Profile preview
Psyence Group
Canadapsyence.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase IIb clinical trial evaluating nature-derived psilocybin in conjunction with psychotherapy as a potential treatment for Adjustment Disorder in Palliative Care in Australia. Two Phase II data readouts are anticipated in 2025.
- Therapeutic areas
- Psychiatry
- Modalities
- Natural psilocybin-based psychedelic medicines
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Psyence Biomedical Ltd. (NASDAQ: PBM)Optimi HealthPsyLabsSouthern Star ResearchEden LabsiNGENū
Beyond the preview
Go deeper on Psyence Group.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Psyence Group.